Page last updated: 2024-08-26

imipenem, anhydrous and Foot Diseases

imipenem, anhydrous has been researched along with Foot Diseases in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (40.00)	18.7374
1990's	2 (40.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
de Haller, R; Mavrakanas, TA; Philippe, J	1
Gibbons, GW; Grayson, ML; Karchmer, AW; McKinnon, PS; Paladino, JA	1
Abbott, TA; Berger, ML; Dasbach, EJ; Hu, XH; Markson, LE	1
Kanat, IO; Pantig-Felix, L; Ross, CD	1
Brown, KR; Calandra, GB; Raupp, W	1

Reviews

1 review(s) available for imipenem, anhydrous and Foot Diseases

Article	Year
Imipenem/cilastatin: its use in the treatment of foot infections in the compromised host. Journal of the American Podiatric Medical Association, 1988, Volume: 78, Issue:7 Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Cyclopropanes; Drug Combinations; Foot Diseases; Humans; Imipenem; Opportunistic Infections; Thienamycins	1988

Trials

1 trial(s) available for imipenem, anhydrous and Foot Diseases

Article	Year
Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1997, Volume: 24, Issue:1 Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cost-Benefit Analysis; Diabetes Mellitus, Type 1; Drug Costs; Drug Therapy; Drug Therapy, Combination; Foot Diseases; Hospital Costs; Hospitalization; Humans; Imipenem; Microbial Sensitivity Tests; Middle Aged; Penicillins; Protease Inhibitors; Sulbactam; Thienamycins	1997

Article

Year

Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1997, Volume: 24, Issue:1

Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cost-Benefit Analysis; Diabetes Mellitus, Type 1; Drug Costs; Drug Therapy; Drug Therapy, Combination; Foot Diseases; Hospital Costs; Hospitalization; Humans; Imipenem; Microbial Sensitivity Tests; Middle Aged; Penicillins; Protease Inhibitors; Sulbactam; Thienamycins

1997

Other Studies

3 other study(ies) available for imipenem, anhydrous and Foot Diseases

Article	Year
Endogenous endophthalmitis in a patient with diabetes and foot osteomyelitis. Canadian journal of diabetes, 2015, Volume: 39, Issue:1 Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Diabetes Complications; Diabetes Mellitus; Endophthalmitis; Female; Foot Diseases; Humans; Imipenem; Osteomyelitis; Radiography; Vancomycin	2015
Antibiotic therapy for foot infections in diabetics. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1997, Volume: 25, Issue:6 Topics: Ampicillin; Cilastatin; Cost-Benefit Analysis; Diabetic Foot; Drug Therapy, Combination; Foot Diseases; Humans; Imipenem; Sulbactam	1997
Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics. Scandinavian journal of infectious diseases. Supplementum, 1987, Volume: 52 Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Cyclopropanes; Diabetes Complications; Drug Combinations; Drug Evaluation; Female; Foot Diseases; Humans; Imipenem; Leg; Male; Middle Aged; Skin Diseases, Infectious; Thienamycins	1987